[Comparison of anti-human and anti-porcine factor VIII antibody titers in patients with hemophilia].
The development of antibodies to factor VIII (circulating anticoagulant, factor VIII inhibitor) is a serious complication following substitution therapy in patients with hemophilia A. These antibodies are rarely specific of human factor VIII, tending to cross-react to a variable extent with factor VIII from other species. Their neutralizing activity is usually weaker against porcine than human factor VIII. In this study, anti-human and anti-porcine factor VIII antibodies (Ab) were measured in 41 patients with severe hemophilia A. The anti-human Ab titers ranged from 0.5 to 1200 BU/ml, and the anti-porcine Ab titers ranged from 0 to 170 BU/ml. The median cross-reactivity was 28% (mean 28.9 +/- 17.2%, range 0-75%). Of the 24 patients with anti-human Ab titers > 5 BU/ml, 11 (46%) had a low anti-porcine Ab level (< or = 5 BU/ml). These patients could be treated effectively with porcine factor VIII concentrate (Hyate: C).
Windyga
J
J
Samodzielna Pracownia Krzepniecia Krwi i Hemostazy Instytutu Hematologii i Transfuzjologii w Warszawie.
Rzymkiewicz
L
L
Lopaciuk
S
S
D000293:Adolescent; D000328:Adult; D000818:Animals; D000906:Antibodies / Q000032:analysis*; D003429:Cross Reactions; D005169:Factor VIII / Q000276:immunology*; D006467:Hemophilia A / Q000276:immunology*; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis*; D008875:Middle Aged; D013045:Species Specificity; D013552:Swine
D000906:Antibodies; D007136:Immunoglobulins; C019158:circulating anticoagulants; D005169:Factor VIII